COMPARE · Reviewed July 30, 2026
BHC vs GRFS
Verdict: Side-by-side breakdown using the Bull Rankings model. BHC scored 70.1, GRFS scored 71.0 — GRFS leads.
Compare another set
BHC
Bausch Health Companies Inc.
70.1
$6.03 · $2.3B
fundamentals as of
Score gap
0.9
GRFS leads
GRFS
Grifols, S.A.
71
$8.20 · $5.6B
fundamentals as of
The model, pillar by pillar (0–100 each)
BHC
stronger →← stronger
GRFS
63
Qualityreturns · margins · balance sheet
56
64
Growthrevenue & earnings expansion
77
86
Valuevaluation vs sector peers
97
GRFS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BHC
GRFS
$1.4bC+
FCF
$562mC+
+10.1%B
Rev
+9.4%B
—
D/E
1.17C
0.2xA
P/S
—
0.01A
PEG
0.19A
—
P/E
10.9xA
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
BHC
GRFS
87% below
Price vs fair valuelower is cheaper
52% below
decline
Growth the price implies10-yr FCF · lower = less priced in
~-3%/yr
+767%
1-yr DCF upside
+58%
+684%
5-yr DCF upside
+107%
+583%
10-yr DCF upside
+205%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BHC
Why this score
- Short track record
GRFS
Why this score
- Raising its dividend
- Foreign reporter (EUR)
The companies
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.3b. Down 31% from 52-week high of $8.69 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Hold with a mean 1-yr target of $7.30 (implying +21% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
GRFSGrifols, S.A.
Why now
Drug Manufacturers - General · market cap $5.6b. Down 25% from 52-week high of $10.88 — deep drawdown territory. PEG 0.19 — paying under fair value for the growth rate.
Moat
FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.